Cargando…

Small cell carcinoma of the oesophagus: experience of an Indian Tertiary Cancer Centre

INTRODUCTION: Small cell carcinoma of the oesophagus (SCCE) is a rare and aggressive tumour with no established standard treatment. METHODS: This is a retrospective study of adult patients with histologically proven SCCE registered between February 2011 and March 2020 at Tata Memorial Hospital in Mu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Panda, Goutam Santosh, Noronha, Vanita, Yadav, Subhash, Joshi, Amit, Patil, Vijay, Menon, Nandini, Kumar, Rajiv, Janu, Amit, Mahajan, Abhishek, Purandare, Nilendu, Agarwal, Jai Prakash, Karimundackal, George, Prabhash, Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cancer Intelligence 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300396/ https://www.ncbi.nlm.nih.gov/pubmed/35919243 http://dx.doi.org/10.3332/ecancer.2022.1393

Ejemplares similares

Leptomeningeal metastasis from non-small cell lung cancer— a post-hoc analysis from four randomised clinical trials
por: Patil, Vijay, et al.
Publicado: (2022)

Prognostic Impact of Baseline Liver Metastasis in ALK Fusion-Positive Metastatic Lung Cancer: A Retrospective Review
por: Khaddar, Satvik, et al.
Publicado: (2022)

ALK-positive advanced non-small cell lung cancer patients with poor performance status: Outcomes in a real-world scenario
por: Singh, Ajaykumar, et al.
Publicado: (2022)

Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer
por: Tibdewal, Anil, et al.
Publicado: (2021)

Real-World Experience of Patients with Inoperable, Stage III Non-small-Cell Lung Cancer Treated with Durvalumab after Chemoradiotherapy: Indian Experience
por: Noronha, Vanita, et al.
Publicado: (2020)

Long-Term Outcomes of Crizotinib Treated ALK-Positive Lung Cancer Patients: A Retrospective Audit of Prospective Data from Resource-Constrained Settings
por: Kapoor, Akhil, et al.
Publicado: (2022)

Association of Immune-Related Adverse Effects and Survival in Solid Tumor Patients Treated with PD1 Inhibitors
por: Kapoor, Akhil, et al.
Publicado: (2022)

Concomitant use of antibiotics and immune checkpoint inhibitors in patients with solid neoplasms: retrospective data from real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2020)

Standard maintenance therapy versus local consolidative radiation therapy and standard maintenance therapy in 1–5 sites of oligometastatic non-small cell lung cancer: a study protocol of phase III randomised controlled trial
por: Tibdewal, Anil, et al.
Publicado: (2021)

The Importance of Brain Metastasis in EGFR Mutation Positive NSCLC Patients
por: Noronha, Vanita, et al.
Publicado: (2014)

Multidisciplinary brain metastasis clinic: is it effective and worthwhile?
por: Rajpurohit, Annu, et al.
Publicado: (2020)

Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer
por: Mahajan, Abhishek, et al.
Publicado: (2023)

Clinical Profile, Practice Pattern, and Outcomes With First-Line Therapy in ALK-Positive Lung Cancer: Real-World Data From Resource-Constrained Settings
por: Kapoor, Akhil, et al.
Publicado: (2022)

Treatment pattern and outcomes in de novo T790M-mutated non-small cell lung cancer
por: Panda, Goutam Santosh, et al.
Publicado: (2022)

ROS1 mutation non-small cell lung cancer—access to optimal treatment and outcomes
por: Joshi, Amit, et al.
Publicado: (2019)

EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?
por: Joshi, Amit, et al.
Publicado: (2017)

Exploring the implications of modified advanced lung cancer inflammation index on outcomes in patients with advanced non-small cell lung cancer
por: Mahajan, Abhishek, et al.
Publicado: (2023)

Randomized phase 3 open label study of quality of life of patients on Pemetrexed versus Erlotinib as maintenance therapy for advanced non squamous non EGFR mutated non small cell lung cancer
por: Patil, Vijay, et al.
Publicado: (2019)

Impact of exon 19 versus exon 21 EGFR-activating mutation on outcomes with upfront pemetrexed–carboplatin chemotherapy
por: Noronha, Vanita, et al.
Publicado: (2017)

Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
por: Joshi, Amit, et al.
Publicado: (2018)

Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?
por: Joshi, Amit, et al.
Publicado: (2017)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2020)

Characteristics and clinical outcomes of pulmonary sarcomatoid carcinoma: experience from Tata Memorial Centre
por: Bondili, Suresh Kumar, et al.
Publicado: (2022)

Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report
por: Abhishek, Mahajan, et al.
Publicado: (2022)

An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
por: Talreja, Vikas T., et al.
Publicado: (2019)

Use of lorlatinib subsequent to crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: Indian experience
por: Talreja, Vikas T., et al.
Publicado: (2019)

ALK Positive Lung Cancer: Clinical Profile, Practice and Outcomes in a Developing Country
por: Noronha, Vanita, et al.
Publicado: (2016)

Prognostic value of a patient-reported functional score versus physician-reported Karnofsky Performance Status Score in brain metastases
por: Agarwal, Jai Prakash, et al.
Publicado: (2017)

Systemic therapy for limited stage small cell lung carcinoma
por: Noronha, Vanita, et al.
Publicado: (2020)

Immune checkpoint inhibitors in patients with solid tumors and poor performance status: A prospective data from the real-world settings
por: Kapoor, Akhil, et al.
Publicado: (2021)

A real‐world data of Immune checkpoint inhibitors in solid tumors from India
por: Noronha, Vanita, et al.
Publicado: (2021)

Clinical Outcome in Definitive Concurrent Chemoradiation With Weekly Paclitaxel and Carboplatin for Locally Advanced Esophageal and Junctional Cancer
por: Noronha, Vanita, et al.
Publicado: (2016)

Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer
por: Patil, Vijay, et al.
Publicado: (2019)

EGFR Mutations in Indian Lung Cancer Patients: Clinical Correlation and Outcome to EGFR Targeted Therapy
por: Noronha, Vanita, et al.
Publicado: (2013)

Maintenance pemetrexed in nonsmall cell lung carcinoma: Outcome analysis from a tertiary care center
por: Pandey, Avinash Vijaykumar, et al.
Publicado: (2015)

Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
por: Majumdar, Swaratika, et al.
Publicado: (2018)

Real-world analysis of the use of lenvatinib in differentiated thyroid cancers
por: Peelay, Zoya, et al.
Publicado: (2023)

An exceptional response to olaparib in relapsed and refractory BRCA2 mutated non-small cell lung cancer in hereditary breast–ovarian cancer syndrome
por: Talreja, Vikas T., et al.
Publicado: (2020)

Chemoradiation in Unresectable Oral Cavity Cancer: A Myth or Reality!
por: Patil, Vijay Maruti, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2duu7fh2ntrdrd3ac9k1nbl11g